riabni
Pharmaranks rates Riabni 3.6/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Riabni (Rituximab-Arrx) is a medication used to treat Rheumatoid Arthritis, Lymphoid Leukemia, Granulomatosis with Polyangiitis, B-Cell Lymphoma.
Rituximab-Arrx · by Amgen Inc
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Rituximab-Arrx
- Form
- Injectable
- Strength
- RITUXIMAB-ARRX 100MG/10ML(10MG/ML)
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- Manufacturer
- Amgen Inc
- FDA application
- BLA761140
Storing Riabni, and how long it keeps
Quoted from this product’s own FDA label. Storage belongs to the product and its device, not to the drug in general — a pen and a tablet of the same medicine are kept completely differently.
- “Store RIABNI vials refrigerated at 2°C to 8°C (36°F to 46°F).”
- “If not used immediately, store diluted RIABNI solutions as shown in Table 1.”
- “Conditions Diluent Used to Prepare Solution for Infusion Diluted RIABNI Solution Storage Conditions 0.”
- “Store RIABNI solution diluted in 0.”
- “Store RIABNI solution diluted in 5% Dextrose Injection, USP refrigerated at 2°C to 8°C (36°F to 46°F) for up to 24 hours after preparation.”
May treat (source: NIH RxClass)
Dosage forms
Injectable
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Riabni treat?
- Riabni (Rituximab-Arrx) may be used to treat rheumatoid arthritis, lymphoid leukemia, granulomatosis with polyangiitis, b-cell lymphoma, mantle-cell lymphoma, microscopic polyangiitis, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Riabni rated?
- pharmaranks gives Riabni a composite score of 3.6 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Riabni?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Riabni. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Riabni?
- Riabni is marketed by Amgen Inc. You can see Amgen Inc's full profile, rating, and other products on pharmaranks.
- Is Riabni a brand-name or generic drug?
- Riabni is a brand-name product with the active ingredient Rituximab-Arrx.
- Is Riabni available over the counter?
- No. Riabni is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Riabni come in?
- Riabni is currently marketed as injectable, per the FDA's National Drug Code Directory.
- Is Riabni FDA-registered?
- Riabni is on record with the U.S. FDA under application number BLA761140. You can verify this on its official FDA label.
- Has Riabni been recalled by the FDA?
- Riabni has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Riabni safe?
- There's no single safe-or-not verdict. pharmaranks gives Riabni a recall-safety score of 72/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about RITUXIMAB-ARRX
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 4 reports naming RITUXIMAB-ARRX — the active ingredient in Riabni, and the FDA flagged 100% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- blood immunoglobulin m decreased1 reports
- chest discomfort1 reports
- colitis1 reports
- infusion related reaction1 reports
- lower respiratory tract infection1 reports
- neutropenia1 reports
- sepsis1 reports
- skin infection1 reports
Read these as a signal, not a rate. A report does not mean RITUXIMAB-ARRX caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved October 26, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
cuprimine
Penicillamine
advil
Ibuprofen
amjevita
Adalimumab-Atto
blincyto
Blinatumomab
chloroquine phosphate
Chloroquine Phosphate
cyltezo
Adalimumab-Adbm
Compare Riabni head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
riabni
72/100